Alzheimer's Disease

FDA Approves Weekly Alzheimer's Dementia Patch

Alzheimer’s disease is the most common cause of dementia, characterized by progressive memory loss and cognitive decline . It is marked by the buildup of amyloid-β plaques and tau tangles in the brain, which damage neurons and impair brain function . With over 6.5 million Americans affected, new treatment options that improve quality of life and ease of use are urgently needed . Recently, the FDA approved a once-weekly transdermal patch delivering donepezil, offering a novel approach to managing symptoms of Alzheimer's dementia .